The Anti-Sintilimab Guidance? US FDA Gives Advice On Oncology Multiregional Trials

Studies should enroll a representative subgroup of US patients based on the incidence or prevalence of cancer in the US, and the comparator arm should use the US standard of care when possible, the FDA says in draft guidance.